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Peptide receptor radioligand therapy (PRRT) has evolved as an important second-line
treatment option in the management of inoperable and metastatic neuroendocrine
neoplasms (NEN). Though high radiation doses can be delivered to the tumors,
complete remission is still rare. Radiosensitization prior to PRRT is therefore considered
to be a promising strategy to improve the treatment effect. In this study, effect and
mechanism of mTOR inhibitors were investigated in a comprehensive panel of five NEN
cell lines (BON, QGP-1, LCC-18, H727, UMC-11), employing assays for cellular
proliferation, clonogenic survival, cell cycle modification and signaling. mTOR inhibition
lead to growth arrest with a biphasic concentration-response pattern: a partial response
at approximately 1 nM and full response at micromolar concentrations (8–48 µM). All cell
lines demonstrated elevated p70S6K phosphorylation yet also increased phosphorylation
of counterregulatory Akt. The pulmonary NEN cell line UMC-11 showed the lowest
induction of phospho-Akt and strongest growth arrest by mTOR inhibitors. Radiation
sensitivity of the cells (50% reduction versus control) was found to range between 4 and 8
Gy. Further, mTOR inhibition was employed together with irradiation to evaluate
radiosensitizing effects of this combination treatment. mTOR inhibition was found to
radiosensitize all five NEN cells in an additive manner with a moderate overall effect. The
radiation-induced G2/M arrest was diminished under combination treatment, leading to
an increased G1 arrest. Further investigation involving a suitable animal model as well as
radioligand application such as 177Lu-DOTATATE or 177Lu-DOTATOC will have to
demonstrate the full potential of this strategy for radiosensitization in NEN.
Keywords: neuroendocrine neoplasms, mTOR inhibitors, peptide receptor radioligand therapy,
radiosensitizer, signalingINTRODUCTION
Peptide receptor radioligand therapy (PRRT) has evolved as an important second-line treatment
option in the management of inoperable and metastatic neuroendocrine neoplasms (NEN). In one
of the earliest studies, comprising 310 GEP-NET patients, treatment with 177Lu-DOTATATE
resulted in complete tumor remission in 2% and partial tumor remission in 28% of the patients, withFebruary 2021 | Volume 10 | Article 5783801
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were found to be mild (1). Recently, the first randomized
multicenter PRRT trial (NETTER-1) evaluated the effect of
combined somatostatin analogs (SSA) and PRRT treatment in
comparison to SSA alone in patients with advanced, progressive
midgut NENs. This phase III trial confirmed previously obtained
results of various studies, demonstrating high response rates and
increased progression-free survival after PRRT (2). Though high
radiation doses (up to 250 Gy) can be delivered to the tumors,
complete remission is still rare (3). Radiosensitization prior to
PRRT is therefore considered to be a promising strategy to
improve the treatment effect.
The serine/threonine kinase mTOR (mammalian target of
rapamycin) is a central integrator of environmental signals such
as nutrients, growth factors and stress, coordinating cell growth
and proliferation. Depending on the proteins it is interacting
with, it can form the two complexes mTORC1 and mTORC2
which have their own distinct downstream effectors. Activated
mTORC1 initiates protein translation by phosphorylation of
S6K1 (also known as p70S6K) and 4EBP1, which in turn
further engage S6 ribosomal protein and eIF4E. At the same
time, activated S6K1 negatively regulates the PI3K-Akt pathway
by inhibition of IRS. Furthermore, mTORC1 promotes cell cycle
progression, inhibits autophagy and controls transcription and
the DNA damage response. On the other hand, mTORC2 is in
charge of cell survival, metabolism and the actin cytoskeleton
(4, 5).
Dysregulated mTOR signaling has been demonstrated in
various cancers, which made mTOR a promising target and
facilitated the development of derivatives of rapamycin, a
naturally occurring mTOR inhibitor. Two examples for FDA-
approved rapalogs with improved pharmacological and solubility
qualities are temsirolimus (CCI-779) and everolimus (RAD001)
(6). They form a complex with FKBP12 before binding to
mTORC1. Inhibition of mTORC1 leads to G1 cell cycle arrest,
reduced tumor angiogenesis, apoptosis induction and enhanced
sensitivity towards DNA-damaging agents (4). However,
rapalogs interrupt not only downstream functions, but also the
S6K1 feedback loop. This results in an upregulation of Akt-
mediated pro-survival signaling and may counteract the
antitumor activity of the inhibitor (7). While rapalogs act as
universal inhibitors of mTORC1, Akt downregulation was
observed only in a few cancer cell lines, indicating a cell-type
specific inhibition of mTORC2 (8). Possibly, cells with PTEN
loss and hyperactive PI3K-Akt signaling may be more dependent
on mTORC1 and show higher sensitivity towards rapalogs (9).
Also, other signaling pathways such as the MAPK cascade seem
to be activated by mTOR inhibition, although this is less well
investigated (10).
Mutations as well as aberrant activations in the PI3K-Akt-
mTOR network were also observed in NENs (11). A series of
clinical trials (RADIANT) resulted in the FDA-approval of
everolimus for advanced pancreatic, non-functional gastrointestinal
and lung NETs (12–15). Treatment with everolimus prolonged
median progression-free survival by 6.4–7.1 months when
compared to the placebo group. Response rates of temsirolimusFrontiers in Oncology | www.frontiersin.org 2were similar to those observed with everolimus, as evaluated in
a phase II study in advanced NENs (16). However, the authors
concluded that temsirolimus, when applied as a single drug,
may yield only modest clinical benefit (17). In addition, it has
to be administered intravenously, whereas everolimus is
available as an oral formulation (18, 19). Recently, a small
phase I study assessed the safety and optimal dose for a
combined treatment of NENs with everolimus and PRRT
(177Lu-DOTATATE) in 16 patients. Overall response was
observed in 44% of patients, and the maximum tolerated dose
for everolimus in combination was found to be 7.5 mg
daily (20).
In this study, effect and mechanism of mTOR inhibitors
were investigated in a comprehensive panel of five NEN cell
lines, employing assays for cellular proliferation, clonogenic
survival, cell cycle modification and signaling. Further, mTOR
inhibition was employed together with irradiation to evaluate
radiosensitizing effects of this combination treatment.MATERIAL AND METHODS
Antibodies
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Protein concentration was determined using the BCA Protein
Assay Kit (Pierce ThermoFisher, Waltham, MA, USA) according
to the manufacturer’s protocol. Colorimetric changes were
measured at 562 nm and the obtained OD values were used to
interpolate protein concentrations from a standard curve
prepared with BSA (0–10 mg/ml).
SDS-PAGE
Protein gel electrophoresis was performed according to standard
protocols. Cell lysates were separated on discontinuous SDS
polyacrylamide gels. 10 µg of protein were diluted in 5x sample
buffer and water in 10 µl total volume, denatured for 5 min at 95°C
and spun down shortly. Polymerized gels were assembled in a
Mini-PROTEAN Tetra tank (Bio-Rad, Hercules, CA, USA), the
upper chamber filled with top buffer (0.1 M Tris-HCl, 0.1 M
Tricine pH 8.25, 0.1 % v/w SDS) and the samples loaded into the
lanes. The lower chamber was filled with bottom buffer (0.2 M
Tris-HCl, pH 8.8) and the gels run at 100 V. The Precision Plus
Kaleidoscope Standard (Bio-Rad) was used as molecular
weight marker.
Western Blotting
Electrophoretically separated proteins were transferred to
nitrocellulose membranes by the wet blot technique. For this,
polyacrylamide gel, membrane, fiber pads and filter paper were
equilibrated in transfer buffer (10 % v/v Rotiphorese 10x SDS-
PAGE, 20 % 96% ethanol in water) for 15 min, stacked and
locked into a cassette. The cassette was placed into a mini Trans-
Blot tank together with an ice pad and a stir bar and filled with
transfer buffer. Blotting was performed for 1 h at 100 V and
constant 350 mA on a magnetic stirrer. Membrane was stained
with ponceau S for assessment of homogenous protein transfer,
destained with water and incubated in blocking buffer (5 % w/v
nonfat dry milk in TBST) for 60 min. After a short wash with
TBST, membrane was incubated with primary antibody
overnight at 4 °C. Membrane was washed three times for
5 min with TBST, incubated with HRP-coupled secondary
antibody diluted in blocking buffer for 60 min at room
temperature and again, washed three times for 5 min with
TBST. Chemiluminescence was induced by addition of 500 µl
SuperSignal West Dura (Pierce ThermoFisher) substrate and
captured with a VersaDoc imaging system (Bio-Rad). Protein
signals were analyzed and quantified with Image Lab software
(Bio-Rad).
Cell Culture
The human neuroendocrine cell lines BON and QGP-1
(pancreatic), LCC-18 (colonic), and H727 and UMC-11
(pulmonary) were cultured in RPMI 1640 containing 10% fetal
calf serum in a humidified atmosphere at 37°C with 5% CO2.
BON cells were a kind gift of Courtney Townsend (University of
Texas, Galveston, TX, USA). LCC-18 cells were kindly donated
by Kjell Öberg (University of Uppsala, Sweden). QGP-1 were
obtained from the Japanese Collection of Research Bioresources,
and H727 and UMC-11 from ATCC (Manassas, VA, USA). CellsFrontiers in Oncology | www.frontiersin.org 3were cultured for no longer than 15 passages. All human cell
lines have been authenticated by DSMZ (Braunschweig,
Germany) using STR profiling.
Drug and Radiation Treatment
Cells were seeded at densities of approximately 5%–10% in 96-,
12-, or 6-well plates and grown overnight. Substances were added
in medium on top of the wells in double concentration for the
indicated final concentrations. Irradiation was performed using
an external caesium-137 source at a dose rate of 1 Gy/min and
further incubation without medium change. For combination
treatments, cells were incubated for 24 h with the respective
substance before radiation or radioligand treatment was applied.
Cell Cycle Analysis
Cell cycle analysis was performed on the basis of DNA content
measurement by flow cytometry. The fluorescence intensity of
DNA binding dyes such as propidium iodide is proportional to
the DNA content of the cell, thereby allowing the discrimination
of cells in sub-G1, G1, S, and G2/M cell cycle phases (21). Cells
were seeded in 12-well plates at a density between 100,000 and
200,000 cells per well and grown overnight before treatment.
Both supernatant and cells were harvested at distinct time points
and fixated with ice cold 70 % ethanol, which was added
dropwise while vortexing to avoid cell aggregation. After
fixation at -20°C for at least 24 h, samples were washed with
PBS and stained with propidium iodide solution (20 µg/ml
propidium iodide, 20 µg/ml RNase A in PBS), containing
RNaseA to remove interfering RNA. For each sample 10,000
events were counted with a flow cytometer measuring forward
and sideward scatter as well as integrated (area, FL2-A) and pulse
(width, FL2-W) red fluorescence. Doublet discrimination was
performed by gating the cells using FL2-A vs. FL2-W, in that way
excluding two aggregating G1 cells that appear to be one single
G2/M cell (22). The gate was applied to the PI histogram, cell
cycle phases marked and the percentages of cells in each phase
quantified with CellQuest Pro software (Becton Dickinson).
Cell Viability—Metabolic Activity and
Cell Number
Cells were seeded in quadruplicates at a density of 5,000 cells in
50 µl medium per well in 96-well plates, grown overnight and
treated as described. After 96 h, metabolic activity was
determined by addition of 100 µl medium containing 0.4 mM
of the redox indicator resazurin. Cells were incubated for 3–4 h
and the resulting fluorescence was measured with an EnVision
Multilabel Plate Reader (excitation filter: TRF 495 nm, emission
filter: dysprosium 572 nm). Subsequently, the supernatant was
removed, cells were fixated with 4 % formaldehyde for 10 min,
stained with DAPI (1 µg/ml in PBS/0.1 % Triton) for another
10 min and wells were covered with 80 µl PBS for image
acquisition. Four fields per well were imaged in an IN Cell
Analyzer 1000 (GE, Reading, UK) using the 4x objective. Image
stacks were analyzed and nuclei counted by IN Cell software. The
values were averaged and normalized as percent of control
treated with vehicle.February 2021 | Volume 10 | Article 578380
Exner et al. mTOR Inhibitors as Radiosensitizers for NENClonogenic Survival
In comparison to short term cell viability assays, the clonogenic
survival assay evaluates the ability of single cells to reproduce and
form colonies, so called clones. Cells were seeded in duplicates
and a density of 5,000 cells in 500 µl medium per well in 12-well
plates and treated as described. Cells were incubated without
medium change for 1–2 weeks. Finally, colonies were fixed with
70 % ethanol for 10 min, stained with crystal violet solution
(0.2 % w/v crystal violet, 20 % methanol in water) for another
10 min and carefully rinsed with tap water. Plates were dried
overnight and digitized with an Odyssey infrared scanner (700
nm channel, intensity 3, 84 µm resolution and medium quality).
For quantification, images were analyzed using the ColonyArea
plugin for ImageJ (23).
Statistics and Data Availability
If not indicated otherwise, dose-response curves were plotted
with GraphPad Prism 5.3 and the data fitted using nonlinear
regression and the variable slope model (four-parameters). As x
values, base 10 logarithms of doses or concentrations were
entered. Statistical analyses were performed with the same
software. The quantitative data for this study have been
permanently published in a public repository accessible via this
link: https://doi.org/10.5281/zenodo.3922212.Frontiers in Oncology | www.frontiersin.org 4RESULTS
Effect of mTOR Inhibitors on NEN Cells
To evaluate the effect of the mTOR inhibitors temsirolimus
and everolimus on neuroendocrine tumor cells, five NEN cell
lines from different organs of origin were studied: BON and
QGP-1 (both from pancreas), LCC-18 (from colon), and H727
and UMC-11 (both from lung). The cells were incubated with
either mTOR inhibitor and two parameters of cell viability were
determined 96 hours after the start of the incubation: metabolic
activity and cell number. In both assays, temsirolimus and
everolimus led to a biphasic inhibition of cell viability in all
five NEN cell lines (Figure 1), displaying similar concentration-
response curves. Metabolic activity as well as cell number
decreased while inhibitor concentrations increased, with two
calculated IC50 values in the nanomolar and micromolar range,
respectively (Table 1). The low nanomolar IC50 differed only
slightly between cell lines and assays (around 1 nM), whereas the
high micromolar IC50 demonstrated greater variation. Here,
values ranged from 8 to 21 µM for temsirolimus and from 30
to 48 µM for everolimus. At nanomolar concentration, the
inhibitors reduced cell viability by 20%–75%, with BON being
the most resistant cell line (20%) and UMC-11 the most sensitive
(75%). In contrast, when applying micromolar concentrations,
all NEN cell lines eventually showed a complete loss of cellA
B
FIGURE 1 | Treatment with mTOR inhibitors results in a biphasic inhibition of NEN cell viability. NEN cell lines were treated with increasing concentrations of
temsirolimus or everolimus (0.1 pM to 100 µM), incubated for 96 h and analyzed for metabolic activity (A) and cell number (B). Data represent mean ± S.E.M. (n=3).TABLE 1 | Summary of IC50 values for mTOR inhibitors.
Temsirolimus Everolimus
Metabolic activity Cell number Metabolic activity Cell number
IC50 low IC50 high IC50 low IC50 high IC50 low IC50 high IC50 low IC50 high
BON 0.26 nM 21.28 µM 0.29 nM 20.61 µM 0.21 nM 48.87 µM 0.92 nM 33.96 µM
QGP-1 0.27 nM 16.67 µM 0.05 nM 15.21 µM 0.27 nM 39.54 µM 0.12 nM 22.28 µM
LCC-18 0.99 nM 15.03 µM 1.23 nM 10.74 µM 0.58 nM 46.24 µM 1.21 nM 31.26 µM
H727 0.47 nM 19.32 µM 0.65 nM 18.85 µM 0.21 nM 34.04 µM 0.26 nM 36.48 µM
UMC-11 0.23 nM 9.08 µM 0.25 nM 8.18 µM 0.27 nM 34.44 µM 0.17 nM 30.76 µMFebruary 2021 | Volume 10 | Article 578380
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status, as BON-SSTR2 and QGP1-SSTR2 cells show no
significant differences under either temsirolimus or everolimus
treatment (Figure S3).
To investigate the inhibitors’ impact on long-term cell
survival and proliferation, clonogenic assays were performed.
Both inhibitors led to similar concentration-response curves,
with the most profound effect on UMC-11 and H727 cells
(Figure 2). In contrast to the cell viability assays, even low
nanomolar concentrations (1 nM, 10 nM) strongly inhibited cell
proliferation in these pulmonary NEN cell lines; by 40%–70% for
H727 and even by 85%–95% for UMC-11. When applying
micromolar concentrations, no colonies were detectable at all.
The other cell lines proved to be more resistant to treatment with
nanomolar concentrations, but showed moderate inhibition of
60%–70 % in the micromolar range.
As mTOR inhibitors are known to inhibit cell cycle
progression in the G1 phase, their effect in the NEN cell lines
was investigated. Cell cycle analysis by flow cytometry was
performed 24 h to 96 h after treatment. Within 24 h,
temsirolimus induced a moderate increase of cells in the G1
phase (Figure 3, Table 2). However, this turned out to be a
transient effect as percentages leveled out after 72 h, at the latest.
H727 cells were not affected at all, with the G1 fraction remaining
almost the same during the whole period.
To investigate how key intracellular effectors were influenced
by mTOR inhibitor treatment, all five NEN cell lines were
analyzed using Western blot. p70S6 kinase, involved in cell
growth and cell cycle progression, is known to be directly
activated by mTOR. Consequently, mTOR inhibition should
lead to decreased p70S6 kinase activation/phosphorylation.Frontiers in Oncology | www.frontiersin.org 5Indeed, this was found in lysates of all five NEN cell lines after
incubation with 1 nM or 100 nM everolimus for 6 or 24 h
(Figure 4). Yet, phospho-Akt levels also increased under
mTOR inhibition, especially in BON and H727 cells. In UMC-
11, phospho-Akt was barely detected, in QGP-1 cells it was
very low, although total Akt was present at similar levels.
Remarkably, the lower concentration of everolimus tended to
lead to higher phospho-Akt levels than the higher concentration.
Phosphorylation status of ERK1/2 was not affected in most cell
lines; only BON showed slightly increased levels after treatment
with everolimus. Neither caspase-3 nor PARP, markers for
apoptosis, were cleaved under these conditions.
In summary, both mTOR inhibitors showed antiproliferative
activity in all five NEN cell lines, caused by suppression of the
mTOR signaling pathway and G1 cell cycle arrest. However, the
cell lines differed in their reaction towards treatment, depending
on counteracting regulation and the extent and duration of G1
cell accumulation. Whereas the rather resistant BON cells
exhibited only a transient G1 arrest, but increased phospho-
Akt levels, the most sensitive UMC-11 cells showed persistent G1
arrest and barely detectable phosphorylation of Akt.
Radiation-Induced Effects on NEN Cells
Before investigating combined mTOR inhibitor and radiation
treatment, the sole impact of irradiation on NEN cells was
assessed by applying a single dose of 0–10 Gy. Cell viability
assays revealed a dose-dependent reduction of metabolic activity
and cell number in all investigated NEN cell lines (Figure 5A).
Cell numbers showed a more prominent reduction (60%–80%)
than metabolic activity (20%–40%). The dose required to lower
cell numbers by 50 % was approximately 8 Gy for H727, 6 Gy forFIGURE 2 | Clonogenic survival of NEN cell lines is affected by mTOR inhibitors. NEN cell lines were seeded at low density, treated with increasing concentrations of
temsirolimus (tem) or everolimus (eve) and incubated for 1–2 weeks until colony formation. Data were normalized to untreated controls and represent mean ± S.E.M.
(n=3-4) or mean only (LCC-18 treated with temsirolimus, n=1).February 2021 | Volume 10 | Article 578380
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FIGURE 3 | Increased accumulation of cells in G1 after mTOR inhibitor treatment. Five NEN cell lines were treated with vehicle (control) or 1 µM temsirolimus. After
(A) 24, (B) 48, (C) 72, and (D) 96 h, incubation samples were collected for cell cycle analysis by flow cytometry. Data show mean ± S.E.M. of n=2–3.TABLE 2 | Percentages of cells in G1 cell cycle after mTOR inhibitor treatment.
Temsirolimus 24h 48h 72h 96h
0 1 µM 0 1 µM 0 1 µM 0 1 µM
BON 66.8 ± 1.2 76.4 ± 1.1 65.9 ± 1.8 66.2 ± 2.1 67.7 ± 0.1 69.5 ± 1.4 64.8 ± 2.7 65.0 ± 3.3
QGP-1 61.1 ± 6.7 74.7 ± 9.0 65.5 ± 13.8 77.4 ± 3.8 79.4 ± 6.4 76.5 ± 4.4 82.7 ± 2.3 79.6 ± 6.0
LCC-18 57.8 ± 3.7 69.9 ± 2.0 65.5 ± 4.8 69.6 ± 3.9 64.3 ± 6.1 64.1 ± 3.3 68.7 ± 4.6 64.1 ± 3.3
H727 61.9 ± 2.8 61.1 ± 3.1 59.5 ± 0.6 61.3 ± 2.5 57.2 ± 2.3 60.6 ± 1.0 58.0 ± 0.8 63.7 ± 3.4
UMC-11 67.0 ± 0.2 72.5 ± 1.7 64.3 ± 3.7 79.1 ± 1.8 69.3 ± 2.3 73.4 ± 7.4 69.8 ± 0.2 74.1 ± 0.5Frontiers in Oncology | www.frontiersin.org 6 February 2021 | Volume 10 | ArtiData show mean ± S.E.M. (n=2–3).FIGURE 4 | Effect of everolimus on intracellular signaling molecules. NEN cell lines were treated with vehicle (0 nM) or everolimus (1 nM, 100 nM) and harvested
after 6 and 24 h. Equal amounts of protein were separated on SDS gels and the indicated molecules detected after western blotting.cle 578380
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contrast to the observed G1 cell cycle arrest after mTOR
inhibitor treatment, irradiation with 10 Gy resulted in a strong
accumulation of cells in G2/M cell cycle phase after 24 h (Figure
5B). QGP-1 cells reached the highest increase (55%), followed by
BON (48%), LCC-18 (38%), H727 (31%) and UMC-11 (31%)
(Table 3). This G2/M cell cycle arrest was retained over time
until 96 h after irradiation in all cell lines, although percentages
partly decreased (Figure S1).
Combined Effect of Temsirolimus and
Irradiation
The five NEN cell lines under investigation were pretreated with
temsirolimus for 24 h, subsequently irradiated and incubated for
another 96 h. As observed before, cell numbers declined when
applying increasing doses of temsirolimus or radiation (Figure 6).
However, combination of both reduced cell numbers to a greater
extent, especially in the low nanomolar range. UMC-11 cells wereFrontiers in Oncology | www.frontiersin.org 7already dramatically affected by temsirolimus alone; therefore, the
additive effect of irradiation was rather moderate when compared to
BON, QGP-1, or LCC-18. The biphasic inhibition pattern of
temsirolimus was retained after irradiation, although the curve
slopes flattened out with increasing radiation doses (Figure 6).
For a detailed analysis, Figure 7 shows the results for the
combination of temsirolimus at 1 nM or 1 µM with 4 Gy of
irradiation. For both concentrations, sequential treatment resulted
in a higher reduction of cell numbers than the respective single
treatments. In the case of pretreatment with 1 µM, cell numbers for
BON and UMC-11 decreased significantly when compared to
irradiation alone (Figure 7B).
In addition, clonogenic survival assays were included to
evaluate the impact of the combined treatment over a longer
period. For this, NEN cells were irradiated with 0–4 Gy after
preincubation with temsirolimus. Combination of both
interventions resulted in clearly impaired cell survival in
comparison to the single treatments (Figure 8). Radiation dosesA B
FIGURE 5 | Irradiation leads to reduced cell viability and G2/M accumulation of NEN cells. (A) NEN cell lines were irradiated with doses of 0 to 10 Gy, incubated for
96 h and analyzed for metabolic activity and cell number. Data represent mean ± S.E.M. (n=2–3). (B) NEN cell lines were irradiated with 10 Gy and samples were
collected after 24 h for cell cycle analysis by flow cytometry. Data are shown as mean ± S.E.M. (n=2–3).TABLE 3 | Percentages of cells in G2/M cell cycle after irradiation.
24h 48h 72h 96h
0 10 Gy 0 10 Gy 0 10 Gy 0 10 Gy
BON 15.6 ± 1.0 63.3 ± 1.6 16.3 ± 0.4 54.5 ± 2.4 17.0 ± 0.6 41.7 ± 2.5 17.0 ± 1.5 38.1 ± 0.6
QGP-1 19.4 ± 5.3 73.9 ± 2.1 18.7 ± 7.3 53.0 ± 3.2 9.9 ± 3.0 46.9 ± 3.0 8.9 ± 1.2 43.2 ± 1.9
LCC-18 17.0 ± 1.2 55.0 ± 3.8 12.5 ± 2.7 48.0 ± 0.9 11.5 ± 1.2 42.8 ± 2.2 10.0 ± 1.6 33.9 ± 0.3
H727 19.6 ± 2.2 50.9 ± 2.8 19.8 ± 1.5 52.4 ± 1.4 20.1 ± 1.2 45.1 ± 1.6 21.1 ± 2.0 37.9 ± 2.1
UMC-11 17.1 ± 0.7 48.5 ± 2.0 19.1 ± 2.0 62.7 ± 1.1 15.5 ± 0.6 51.2 ± 3.3 13.9 ± 0.9 47.5 ± 2.6February 2021 | Volume 10 | ArtiData show mean ± S.E.M. (n=2–3).FIGURE 6 | Additive effect of temsirolimus and irradiation on NEN cell numbers. NEN cell lines were pretreated with increasing concentrations of temsirolimus (0.01
nM to 20 µM) for 24 h before irradiation. Cell number was determined 96 h after irradiation with different doses of 0–10 Gy. Graphs show mean ± S.E.M. (n=2–3).cle 578380
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(data not shown). This is in strong contrast to the shorter cell
number assays, where the highest dose of 10 Gy still resulted in
detectable signals (Figure 6). Irradiation with 4 Gy alone inhibited
cell numbers only by 32% (BON), 38 % (QGP-1), 44% (LCC-18),
31% (H727) and 56% (UMC-11) (Figure 7). Cell survival in the
clonogenic assay on the other hand was lowered by 45% (BON),
55% (QGP-1), 13% (LCC-18), 75 % (H727), and 92% (UMC-11)
(Figure 8). In BON andH727, pretreated with 1 nM temsirolimus,
and in QGP-1, pretreated with 1 µM, additional irradiation with
4 Gy significantly decreased cell survival in comparison to
temsirolimus alone (Figure 9). The beneficial impact of aFrontiers in Oncology | www.frontiersin.org 8combined treatment regimen was seen in all cell lines and
lowered cell survival down to ≤ 20%.
The previous analysis of cell cycle distribution following the
respective single treatments revealed increased cell accumulation in
G1 after mTOR inhibitor treatment, or in G2/M after irradiation.
Here, the combined effect of both treatments was evaluated by
preincubating the respective cell lines with 1 µM temsirolimus for
24 h before irradiating them with 10 Gy. In all five NEN cell lines,
mTOR inhibitor pretreatment resulted in a diminished radiation-
induced G2/M arrest after 24 h (Figure 10). Correspondingly, the
G1 fraction increased. In QGP‑1 cells, the impact of combined
treatment on cell cycle distribution was most profound. ComparedA
B
FIGURE 7 | Detailed analysis of cell numbers for combined treatment of temsirolimus and 4 Gy. NEN cell lines were pretreated with 1 nM (A) or 1 µM (B)
temsirolimus for 24 h before irradiation with 4 Gy. Cell number was determined 96 h after irradiation. Graphs show mean ± S.E.M. (n=2–3). Evaluated with one-way
ANOVA (Kruskal-Wallis test) and Dunn’s posttest, *P ≤ 0.05. tem, temsirolimus; IR, irradiation.FIGURE 8 | Additive effect of temsirolimus and irradiation on NEN cell survival. NEN cell lines were seeded at low density, treated with increasing concentrations of
temsirolimus for 24 h before irradiation with 0–4 Gy. Cells were incubated for 1–2 weeks until colony formation. Data were normalized to untreated controls and
represent mean ± S.E.M. (n=2–3).February 2021 | Volume 10 | Article 578380
Exner et al. mTOR Inhibitors as Radiosensitizers for NENto irradiation only, the G2/M fraction decreased by 49% (from 74%
to 38%), while cells in G1 increased by 212% (from 16% to 50%)
(Table 4). Similarly, UMC-11, LCC-18, and BON cells showed a
decrease in G2/M and an increase in G1. Even in H727 cells, whichFrontiers in Oncology | www.frontiersin.org 9did not show any G1 cell accumulation when applying temsirolimus
alone, combined treatment led to an increase of the G1 fraction after
24 h. This reduced G2/M arrest after combinatorial treatment was
maintained for up to 96 h in UMC-11 and H727 (Figure S2),A
B
FIGURE 9 | Detailed analysis of cell survival for combined treatment of temsirolimus and 4 Gy. NEN cell lines were pretreated with 1 nM (A) or 1 µM (B)
temsirolimus for 24 h before irradiation with 4 Gy. Cell survival was determined 1–2 weeks after irradiation. Graphs show mean ± S.E.M. (n=2–3). Evaluated with
one-way ANOVA (Kruskal-Wallis test) and Dunn’s posttest, *P ≤ 0.05. tem, temsirolimus; IR, irradiation.A B
FIGURE 10 | Temsirolimus pretreatment abrogates radiation-induced G2/M cell accumulation. NEN cell lines were incubated with 1 µM temsirolimus (tem) or vehicle
(ctrl) for 24 h before irradiation. For assessment of cell cycle distribution pretreated NEN cells were collected 24 h after irradiation with 10 Gy (IR, tem+IR), stained
with propidium iodide and analyzed by flow cytometer. Data are shown as bar diagrams with mean ± S.E.M. (n=2–3) (A) or as DNA histograms of one representative
experiment (B).February 2021 | Volume 10 | Article 578380
Exner et al. mTOR Inhibitors as Radiosensitizers for NENwhereas it leveled out after 48 h in BON and LCC-18 cells. QGP-1
cells slowly returned to the irradiation-like cell cycle distribution
with complete adjustment after 96 h. The sub-G1 fraction as a
measure for nuclear debris was increased after irradiation only or
after combination with temsirolimus pretreatment in all
investigated cell lines.
In summary, combination of mTOR inhibitor treatment and
irradiation indicated superiority compared to the single treatments
as proven by increased decrease of cell numbers and cell survival.
Preincubation with temsirolimus abrogated the irradiation-induced
G2/M arrest in all NEN cell lines under investigation.DISCUSSION
PRRT has become an essential treatment option for advanced
NEN. It demonstrated increased progression-free survival when
compared to chemotherapy, radiation, and intervention with
somatostatin analogs (SSAs). Objective response rates range
between 15 and 35 % (24). However, complete remissions are
still very rare, although PRRT delivers high doses specifically to
the tumor (3). In contrast, similar nuclear therapies such as
radioiodine therapy for thyroid cancers or radioimmunotherapy
for B-cell non-Hodgkin’s lymphoma achieve complete
remissions in 30% or 75% of all cases, respectively (25, 26). It
was hypothesized that other established NEN therapies such as
mTOR inhibitors may have a radiosensitizing effect, leading to a
beneficial impact on the outcome of PRRT. Therefore, this work
evaluated the radiosensitizing potential of mTOR inhibitor
treatment prior to irradiation in a panel of five NEN cell lines
of different origin.
First, the impact of the two mTOR inhibitors temsirolimus
and everolimus on cellular processes was validated for the
utilized NEN cell lines. Proliferation assays revealed a biphasic
inhibition of metabolic activity and cell number, with two
resulting IC50 values for both substances in all five cell lines.
Whereas nanomolar concentrations led to a moderate
antiproliferative effect, micromolar concentrations suppressed
cell viability completely. This is in line with a report from Shor
et al. that also described a low-dose and high-dose effect of
temsirolimus in different cancer cell lines (27). In addition to the
well-known FKBP12-dependent binding of temsirolimus to
mTOR, they suggest a second FKBP12 independent
mechanism, which might be responsible for the profound high
dose effect. Although the determined low-dose IC50 values were
approximately 1 nM for all cell lines and both inhibitors, efficacyFrontiers in Oncology | www.frontiersin.org 10(amplitude of the effect) differed between the investigated cell
lines. Pulmonary UMC-11 cells were found to be highly drug-
sensitive, as cell viability was reduced by 75% after treatment at
nanomolar concentrations, whereas BON cells proved to be
rather resistant (20 % reduction). Long-term clonogenic
survival assays over up to 2 weeks confirmed these results.
Signaling and cell cycle analysis were conducted to further
elucidate the observed response in these cell lines. Similar to a
study by Hurvitz et al. in breast cancer cell lines (28), inhibition
of p70S6 kinase, a downstream target of mTOR, was achieved in
all NEN cell lines, but did not correlate with their susceptibility as
measured by cell viability and survival. Yet, phospho-p70S6
kinase levels were only monitored for 24 h after treatment and
later time points might reveal divergent response patterns. The
high sensitivity of UMC‑11 might be explained by a constantly
elevated fraction of cells in the G1 cell cycle phase, up to 96 h
after treatment. In addition, mTOR inhibition did not result in a
counteracting phospho-Akt upregulation in these cells - a
frequently observed resistance mechanism in tumor cells based
on loss of the negative S6K feedback loop on IRS and PI3K. In
comparison, the rather resistant BON cells show only transient
G1 cell accumulation of up to 24 to 48 h and a clear increase of
phospho-Akt and phospho-ERK levels, indicating several escape
pathways. This is in line with a report by Zitzmann et al., that
investigated the effect of everolimus on proliferation, cell cycle
distribution and signaling of BON cells (29). In contrast to their
results, this study could not confirm apoptosis induction in these
cells , though investigating similar time points and
concentrations. Interestingly, between these very distinct cases
of BON and UMC-11 cells, intermediate phenotypes seem to
exist. For example, despite a clear Akt activation and a rather
weak and transient G1 cell accumulation, clonogenic survival of
H727 was strongly reduced after mTOR inhibition. QGP-1 cells
behaved similar to BON cells (both expressing mutant p53) with
regard to cell viability and survival assays, with a transient but
very strong G1 cell accumulation. On the other hand, QGP-1
cells did not activate Akt upon mTOR inhibition.
Cell cycle checkpoints at G1/S or G2/M phase transitions are
important control mechanisms to maintain genomic integrity
within the cell in response to environmental stress and DNA
damaging agents such as irradiation. Their activation is mediated
by a complex signaling network including cyclins, cyclin-
dependent kinases and the key modulator p53, which is
primarily involved in G1 cell cycle arrest (30). In the case of
extensive and irreparable damage, cells go into apoptosis. It has
been shown that mTOR inhibitors induce a p53-independent G1TABLE 4 | Percentages of cells in G1 and G2/M cell cycle 24 h after irradiation.
G1 G2/M
ctrl tem IR tem + IR ctrl tem IR tem + IR
BON 66.7 ± 1.2 76.4 ± 1.1 22.9 ± 1.5 33.4 ± 2.4 15.6 ± 1.0 11.5 ± 0.0 63.3 ± 1.6 49.1 ± 1.5
QGP-1 61.1 ± 6.7 74.7 ± 9.0 15.6 ± 0.6 49.5 ± 7.2 19.4 ± 5.3 15.2 ± 5.7 73.9 ± 2.1 38.4 ± 5.9
LCC-18 57.8 ± 3.7 69.9 ± 2.0 19.7 ± 1.5 39.7 ± 7.1 17.0 ± 1.2 11.0 ± 1.5 55.0 ± 3.8 34.8 ± 2.2
H727 61.9 ± 2.8 61.1 ± 3.1 28.2 ± 1.9 36.3 ± 0.2 19.6 ± 2.2 19.8 ± 3.1 50.9 ± 2.8 45.3 ± 1.9
UMC-11 67.0 ± 0.2 72.5 ± 1.7 34.7 ± 0.8 59.9 ± 3.2 17.1 ± 0.7 14.7 ± 0.1 48.5 ± 2.0 27.4 ± 3.3February 2021 | Volume 10 | ArtiData show mean ± S.E.M. (n=2–3).cle 578380
Exner et al. mTOR Inhibitors as Radiosensitizers for NENcell cycle arrest by an impaired translation of cyclin D1 and an
enhanced expression of p27Kip1 (31–33). Neither molecule was
included in this analysis, but differences in their expression upon
mTOR inhibition might further explain the varying treatment
susceptibility of the single cell lines. The permanent G1 cell cycle
accumulation of drug-sensitive UMC-11 cells indicates a likely
influence of the cells’ capability to stay in this arrest over time.
Several genetic alterations have been associated with mTOR
sensitivity such as PTEN-deficiency (34), a distinct SNP in
FGFR4 (35), or PIK3CA mutations (36). Undoubtedly, an
increased basal activation of mTOR and its signaling pathway
plays an important role for the outcome of mTOR inhibitor
treatment. Nevertheless, clinical biomarkers for a reliable
response prediction were not identified so far (37). In
conclusion, this study verifies the expected effects of mTOR
inhibitors in vitro and further complements the reported results
for pancreatic neuroendocrine BON and QGP-1 cells (29, 34) by
evaluating an extended NEN cell line panel that includes
pulmonary neuroendocrine H727 and UMC-11 as well as
colonic neuroendocrine LCC-18 cells.
In line with many reports that analyzed radiation effects and
DNA damage responses in cancer cells, all investigated NEN cell
lines revealed an accumulation at the G2/M junction, which was
retained over time. Radiation susceptibility differed only slightly
between cell lines as determined by cell counting. Although
DNA-damaging radiation is primarily associated with G1
arrest, it was postulated that most cancer cells lack a functional
G1 checkpoint due to mutations in the key molecule p53.
Therefore, they are more reliant on the pre-mitotic G2/M
checkpoint for repair of potentially lethal damage and display
a strong G2/M arrest upon irradiation (38–40). Cell viability and
survival assays revealed the superiority of combining mTOR
inhibitors with irradiation in comparison to either single
application. In all NEN cell lines under investigation, this
treatment strategy exhibited an additive inhibitory effect.
Interestingly, the response of the drug-sensitive drug-sensitive
UMC-11 cells was barely enhanced by this approach as mTOR
inhibition already impaired survival to a great extent. As
discussed before, mTOR inhibitors induced a G1 cell cycle
accumulation, whereas after irradiation cells accumulated in
G2/M. In combination, pretreatment with temsirolimus clearly
diminished radiation-induced G2/M arrest in all five NEN cell
lines. Thus, it can be hypothesized that temsirolimus prevents
DNA damage repair processes that normally occur during G2/M
arrest. Thereby, cells with unrepaired DNA lesions may
prematurely enter mitosis and undergo the so called mitotic
catastrophe, which is distinct from apoptotic cell death (41, 42).
Other groups addressing the radiosensitizing effect of everolimus
consistently reported an enhanced inhibition of cell growth in
vitro and in vivo when applying the combinatorial treatment
regimen. However, cell cycle distribution analyses revealed
different outcomes. Su et al. observed no difference in G2/M
between everolimus with and without radiation in Ras-
transformed cells (43). Possibly, the chosen concentration of
30 nM was too low to uncover the G2/M abrogation. In contrast,
Nassim et al. reported an increase of both G1 and G2/M whenFrontiers in Oncology | www.frontiersin.org 11combining everolimus with radiation in bladder cancer cells (44).
They suggest that the everolimus-induced G1 arrest confers an
enhanced sensitivity for the following radiation as fewer cells
were counted in the rather radioresistant S‑phase (45). However,
in NEN cell lines the proportion of S-phase cells was relatively
unaffected. It must be further noted, that the length of
pretreatment differed between the studies, which might have a
significant impact on the evaluated parameters. In line with the
presented work, Wang et al. reported an abrogation of the
radiation-induced G2/M arrest in pancreatic cells, but after
pretreatment with metformin (46).
One of the limitations of this study is the use of external beam
irradiation instead of radioligands used in PRRT, such as 177Lu-
DOTATOC or 177Lu-DOTATATE. The external beam irradiation
used was from a calibrated 137Cs source. It delivers reproducible,
stable and precise dose levels to cultured cells and is easily accessible.
Similar to 177Lu, 137Cs is a combined beta/gamma emitter. Though
both isotopes have a similar beta emission energy, their effect on
living cells will differ to a small extent. In contrast to external beam
irradiation, PRRT with 177Lu-coupled SSA only targets cells
expressing somatostatin receptors (SSTR), preferentially SSTR2.
However, for all NEN cell lines under investigation in this study,
we have previously demonstrated low target expression and a lack of
binding of the SSA octreotide. All five cell lines cells showed 10- to
1000-fold lower SSTR2mRNA levels than humanNEN tissues (47).
Consequently, external beam irradiation had to be utilized. In
comparison to targeted PRRT with 177Lu-coupled peptides, this
type of irradiation is undirected and affects cells independent of
their receptor status. It would certainly be of great interest to see the
experimental outcome in a human SSTR2-transfected NEN cell
model. The use of in vitro methods only represents another
limitation of this study. Though it features a rather broad,
systematic approach involving five NEN cell lines of different
origin, the results will not cover any effects ionizing radiation, e.g.
in the form of radioligand therapy, might have in the context of a
tumor, such as effects on tumor-associated fibroblasts, immune
cells, the circulation and other components of the tumor
microenvironment. In addition, some of the cell lines used (BON,
QGP1) have been characterized with regards to their genetic profile
and have been shown to feature mutations untypical of
neuroendocrine tumors or even neuroendocrine cancers (e.g. in
TP53, TSC2) (48, 49). While they have been used as models in the
literature a lot, their behavior may not be predictive of typical NETs.
Novel cell lines such as P-STS (50) or NT3 (51), primary cultures or
organoids may represent alternative models to be used in the future.
On the other hand, even NECs with mutant TP53 might be
sensitized for mTOR inhibition by PRRT. In addition to
treatment with 177Lu-DOTATOC or 177Lu-DOTATATE, the
evaluation of the antagonistic peptide ligand 177Lu-DOTA-JR11
could be an interesting part of such a combinatorial in vivo study.
Recently, a favorable toxicity profile has been found for the
combination of temsirolimus and 177Lu-DOTATATE in rats (52).
In addition, further translational research is required to assess the
potential of the combination of PRRT and mTOR inhibitors in
pulmonary carcinoids as well as in G2 and G3 NEN. Likewise,
careful preclinical evaluation in a suitable animal model isFebruary 2021 | Volume 10 | Article 578380
Exner et al. mTOR Inhibitors as Radiosensitizers for NENwarranted, especially as the combination of 177Lu-DOTATATE and
RAD001 had led to enhanced metastasis in a rat NEN model (53).
The future application of somatostatin antagonists as single agents
or together with mTOR inhibitors as well as other substances may
provide new opportunities for SSTR-based therapies with improved
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